{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:53:32Z","timestamp":1769975612871,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jns.2016.11.016","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T04:30:53Z","timestamp":1478752253000},"page":"92-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up"],"prefix":"10.1016","volume":"372","author":[{"given":"M.E.","family":"Evangelopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Andreadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Koutsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Koutoulidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Anagnostouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Katsika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.S.","family":"Evangelopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Evdokimidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kilidireas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2016.11.016_bb0005","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2016.11.016_bb0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.11.016_bb0015","first-page":"246","article-title":"Immonosuppressive therapy is more effective than interferon in neuromyelitis optica","volume":"13","author":"Papaeix","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2016.11.016_bb0020","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2016.11.016_bb0025","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2016.11.016_bb0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.11.016_bb0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2016.11.016_bb0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.11.016_bb0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jneuroim.2015.11.006","article-title":"Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination","volume":"290","author":"Mauer","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2016.11.016_bb0050","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.11.016_bb0055","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on the diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2016.11.016_bb0060","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"10","author":"Dalakas","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.jns.2016.11.016_bb0065","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1756285616632653","article-title":"An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica","volume":"9","author":"Collongues","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2016.11.016_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.11.016_bb0075","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.11.016_bb0080","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.11.016_bb0085","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.11.016_bb0090","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2016.11.016_bb0095","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability on neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.jns.2016.11.016_bb0100","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jns.2016.11.016_bb0105","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2016.11.016_bb0110","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Zephir","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2016.11.016_bb0115","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.11.016_bb0120","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/393568","article-title":"Neuromyelitis optica spectrum disease with positive autoimmune indices: a case report and review of the literature","volume":"2011","author":"Evangelopoulos","year":"2011","journal-title":"Case Rep. Med."},{"key":"10.1016\/j.jns.2016.11.016_bb0125","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon-beta treatment in neuromyelitis optica","volume":"67","author":"Palace","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.11.016_bb0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2016.11.016_bb0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2013.02.024","article-title":"Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases","volume":"328","author":"Gredler","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.11.016_bb0140","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.11.016_bb0145","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin 4 in the long term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.jns.2016.11.016_bb0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of Hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16307110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16307110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T02:39:24Z","timestamp":1601174364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X16307110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":30,"alternative-id":["S0022510X16307110"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2016.11.016","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2016.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}